{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:05:23Z","timestamp":1794855923492,"version":"4.9.1"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,9]],"date-time":"2027-02-09T00:00:00Z","timestamp":1802131200000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK 111834"],"award-info":[{"award-number":["R01 DK 111834"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0306"],"award-info":[{"award-number":["HT9425-23-1-0306"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0570"],"award-info":[{"award-number":["W81XWH-16-1-0570"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0516"],"award-info":[{"award-number":["W81XWH-21-1-0516"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0665"],"award-info":[{"award-number":["W81XWH-21-1-0665"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-24-1-0014"],"award-info":[{"award-number":["HT9425-24-1-0014"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008333","name":"The University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01CX002478-01A1"],"award-info":[{"award-number":["I01CX002478-01A1"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX004944"],"award-info":[{"award-number":["I01BX004944"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX004944-01"],"award-info":[{"award-number":["I01BX004944-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cytogfr.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:48:24Z","timestamp":1770104904000},"page":"124-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC"],"prefix":"10.1016","volume":"88","author":[{"given":"Dhanisha Sulekha","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda","family":"Salcedo-Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utpreksha","family":"Vaish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhiram Beena","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryansh","family":"Suryansh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikiran","family":"Chatre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejeshwar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivaan","family":"Dudeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cytogfr.2026.01.009_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/AS9.0000000000000096","article-title":"Surgical resection or ablation for recurrent pancreatic ductal adenocarcinoma: an analysis of oncologic outcomes according to the recurrence type","volume":"2","author":"Lee","year":"2021","journal-title":"Ann. Surg. Open"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.01.009_bib5","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib7","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol."},{"issue":"19","key":"10.1016\/j.cytogfr.2026.01.009_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13195028","article-title":"Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches","volume":"13","author":"Truong","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-020-00341-1","article-title":"Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.01.009_bib10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","article-title":"Stromal biology and therapy in pancreatic cancer: a changing paradigm","volume":"64","author":"Neesse","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"Eur. J. Med Res"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/mthe.2002.0570","article-title":"Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model","volume":"5","author":"Putzer","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1323198","article-title":"Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma","volume":"15","author":"Joseph","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1569884","article-title":"Immune checkpoint inhibitors in pancreatic adenocarcinoma: a systematic review and meta analysis of clinical outcomes","volume":"15","author":"Al-Khinji","year":"2025","journal-title":"Front Oncol."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.01.009_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1326927","article-title":"SON-1210 - a novel bifunctional IL-12 \/ IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy","volume":"14","author":"Cini","year":"2023","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1017701","article-title":"Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer","volume":"4","author":"Cany","year":"2015","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.01.009_bib19","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med"},{"issue":"18","key":"10.1016\/j.cytogfr.2026.01.009_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251810166","article-title":"Development of mRNA lipid nanoparticles: targeting and therapeutic aspects","volume":"25","author":"Liu","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-032713-120211","article-title":"Insights into cytokine-receptor interactions from cytokine engineering","volume":"33","author":"Spangler","year":"2015","journal-title":"Annu Rev. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-024-01888-z","article-title":"Cell-cell communication: new insights and clinical implications","volume":"9","author":"Su","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/icb.2015.15","article-title":"Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies","volume":"93","author":"Kufareva","year":"2015","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib24","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13233","article-title":"Pancreatic stellate cells: key players in pancreatic health and diseases (Review)","volume":"30","author":"Wang","year":"2024","journal-title":"Mol. Med Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010108","article-title":"Activation and regulation of pancreatic stellate cells in chronic pancreatic fibrosis: a potential therapeutic approach for chronic pancreatitis","volume":"12","author":"Kong","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fphys.2012.00344","article-title":"Pancreatic stellate cells: a starring role in normal and diseased pancreas","volume":"3","author":"Apte","year":"2012","journal-title":"Front Physiol."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/gut.50.4.535","article-title":"Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis","volume":"50","author":"Mews","year":"2002","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.cytogfr.2026.01.009_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ncpgasthep0881","article-title":"Mechanisms of disease: chronic inflammation and cancer in the pancreas--a potential role for pancreatic stellate cells?","volume":"4","author":"Algul","year":"2007","journal-title":"Nat. Clin. Pr. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib29","article-title":"Molecular mechanism underlying lymphatic metastasis in pancreatic cancer","author":"Xiao","year":"2014","journal-title":"Biomed. Res Int 2014"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"Pt 2","key":"10.1016\/j.cytogfr.2026.01.009_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.semcancer.2022.03.021","article-title":"Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment","volume":"86","author":"Bhatia","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.01.009_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-induced JAK\/STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"issue":"49","key":"10.1016\/j.cytogfr.2026.01.009_bib33","doi-asserted-by":"crossref","first-page":"81110","DOI":"10.18632\/oncotarget.13212","article-title":"Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41419-021-03920-4","article-title":"TNF-alpha induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma","volume":"12","author":"Adjuto-Saccone","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib35","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.01.009_bib36","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1002\/cam4.1824","article-title":"Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8","volume":"7","author":"Chen","year":"2018","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.01.009_bib37","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41416-019-0595-2","article-title":"Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages","volume":"121","author":"Chen","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.cytogfr.2026.01.009_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122860","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges","volume":"13","author":"Poh","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/labinvest.2013.69","article-title":"M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4\/IL-10 signaling pathway","volume":"93","author":"Liu","year":"2013","journal-title":"Lab Invest"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib40","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.4049\/jimmunol.0902609","article-title":"Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer","volume":"185","author":"Gnerlich","year":"2010","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.01.009_bib41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ccr.2014.03.014","article-title":"Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia","volume":"25","author":"McAllister","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.gastro.2018.03.041","article-title":"Immune cell production of interleukin 17 induces stem cell features of pancreatic intraepithelial neoplasia cells","volume":"155","author":"Zhang","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1158\/2159-8290.CD-15-0843","article-title":"IL35-producing B cells promote the development of pancreatic neoplasia","volume":"6","author":"Pylayeva-Gupta","year":"2016","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.01.009_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154016","article-title":"Cytokines as biomarkers of pancreatic ductal adenocarcinoma: a systematic review","volume":"11","author":"Yako","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib45","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4161\/cbt.6.7.4328","article-title":"L. Min, IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells","volume":"6","author":"Feurino","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib46","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3389\/fimmu.2018.01044","article-title":"Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment","volume":"9","author":"Foucher","year":"2018","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.01.009_bib47","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.cytogfr.2026.01.009_bib48","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1042\/CS20191211","article-title":"Emerging roles for the IL-6 family of cytokines in pancreatic cancer","volume":"134","author":"van Duijneveldt","year":"2020","journal-title":"Clin. Sci. (Lond. )"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib49","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0016-5085(03)01064-3","article-title":"Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer","volume":"125","author":"Scholz","year":"2003","journal-title":"Gastroenterology"},{"issue":"14","key":"10.1016\/j.cytogfr.2026.01.009_bib50","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","article-title":"STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis","volume":"71","author":"Corcoran","year":"2011","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.cytogfr.2026.01.009_bib51","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1101\/gad.1549407","article-title":"Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis","volume":"21","author":"Ancrile","year":"2007","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.01.009_bib52","first-page":"113","article-title":"Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer","volume":"38","author":"Zhang","year":"2008","journal-title":"Ann. Clin. Lab Sci."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10620-008-0390-z","article-title":"Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis","volume":"54","author":"Talar-Wojnarowska","year":"2009","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.01.009_bib54","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/cncr.20672","article-title":"Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis","volume":"101","author":"Ebrahimi","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib55","first-page":"183","article-title":"Proinflammatory cytokines: an insight into pancreatic oncogenesis","volume":"69","author":"Miron","year":"2010","journal-title":"Roum. Arch. Microbiol Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jjco\/28.1.12","article-title":"Elevated serum interleukin-6 levels in patients with pancreatic cancer","volume":"28","author":"Okada","year":"1998","journal-title":"Jpn J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.cytogfr.2026.01.009_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215481","article-title":"Oncogenic KRAS-induced feedback inflammatory signaling in pancreatic cancer: an overview and new therapeutic opportunities","volume":"13","author":"Bansod","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1258538","article-title":"An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib59","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.cytogfr.2026.01.009_bib60","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-17-3401","article-title":"Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic\/predictive significance","volume":"24","author":"Wartenberg","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010194","article-title":"Macrophage and neutrophil interactions in the pancreatic tumor microenvironment drive the pathogenesis of pancreatic cancer","volume":"14","author":"Pratt","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.01.009_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/biom11060901","article-title":"Immune cell modulation of the extracellular matrix contributes to the pathogenesis of pancreatic cancer","volume":"11","author":"Ahmad","year":"2021","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.01.009_bib63","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/gutjnl-2014-307075","article-title":"SOX9 regulates ERBB signalling in pancreatic cancer development","volume":"64","author":"Grimont","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-019-0966-6","article-title":"TAMing pancreatic cancer: combat with a double edged sword","volume":"18","author":"Lankadasari","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib65","article-title":"Inflammatory cytokine signaling during development of pancreatic and prostate cancers","author":"Liou","year":"2017","journal-title":"J. Immunol. Res 2017"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa345","article-title":"Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer","volume":"22","author":"Ju","year":"2021","journal-title":"Brief. Bioinform"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.01.009_bib67","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.bjc.6604329","article-title":"Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia","volume":"98","author":"Moniaux","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.01.009_bib68","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/MPA.0000000000001690","article-title":"Neutrophil gelatinase-associated lipocalin protects acinar cells from cerulein-induced damage during acute pancreatitis","volume":"49","author":"Bhatia","year":"2020","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.01.009_bib69","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/ajg.2010.23","article-title":"Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis","volume":"105","author":"Chakraborty","year":"2010","journal-title":"Am. J. Gastroenterol."},{"issue":"24","key":"10.1016\/j.cytogfr.2026.01.009_bib70","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1158\/1078-0432.CCR-21-1591","article-title":"Mucin expression and splicing determine novel subtypes and patient mortality in pancreatic ductal adenocarcinoma","volume":"27","author":"Thompson","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"2020","key":"10.1016\/j.cytogfr.2026.01.009_bib71","article-title":"The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis","volume":"11","author":"Masucci","year":"1749","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.01.009_bib72","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.devcel.2019.04.011","article-title":"Exosome-mediated metastasis: communication from a distance","volume":"49","author":"Wortzel","year":"2019","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1541-7786.MCR-16-0163","article-title":"Exosomal annexin II promotes angiogenesis and breast cancer metastasis","volume":"15","author":"Maji","year":"2017","journal-title":"Mol. Cancer Res"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.01.009_bib75","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ncb3169","article-title":"Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver","volume":"17","author":"Costa-Silva","year":"2015","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib76","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","article-title":"Pre-metastatic niche: formation, characteristics and therapeutic implication","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118886","article-title":"Exosomal proteins as drivers of metastasis to distant organs","volume":"193","author":"Martinez-Espinosa","year":"2025","journal-title":"Biomed. Pharm."},{"issue":"25","key":"10.1016\/j.cytogfr.2026.01.009_bib78","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/onc.2013.272","article-title":"Inflammatory chemokines and metastasis--tracing the accessory","volume":"33","author":"Borsig","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030046","article-title":"CXCR4\/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model","volume":"7","author":"Wendel","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cytogfr.2026.01.009_bib80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastas.. Rev."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/imr.12982","article-title":"Cancer-associated fibroblasts: key players in shaping the tumor immune microenvironment","volume":"302","author":"Desbois","year":"2021","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib82","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/1535-7163.MCT-18-0850","article-title":"TGF\u03b2 blockade augments PD-1 inhibition to promote T-cell-mediated regression of pancreatic cancer","volume":"18","author":"Principe","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.01.009_bib83","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.01.009_bib84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.33696\/cancerimmunol.7.109","article-title":"Targeting FAK to potentiate immune checkpoint therapy in solid tumors","volume":"7","author":"Stanley","year":"2025","journal-title":"J Cancer Immunol (Wilmington)"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.01.009_bib85","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-21-0083","article-title":"Targeting tumor-stromal IL6\/STAT3 signaling through IL1 receptor inhibition in pancreatic cancer","volume":"20","author":"Dosch","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.01.009_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155006","article-title":"Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner","volume":"8","author":"Ware","year":"2023","journal-title":"JCI Insight"},{"issue":"50","key":"10.1016\/j.cytogfr.2026.01.009_bib87","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.01.009_bib88","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med"},{"issue":"46","key":"10.1016\/j.cytogfr.2026.01.009_bib89","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.cytogfr.2026.01.009_bib90","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.cytogfr.2026.01.009_bib91","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108598","article-title":"CCL2-mediated monocytes regulate immune checkpoint blockade resistance in pancreatic cancer","volume":"106","author":"Li","year":"2022","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib93","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O'Hara","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6024","key":"10.1016\/j.cytogfr.2026.01.009_bib94","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib95","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res"},{"issue":"19","key":"10.1016\/j.cytogfr.2026.01.009_bib96","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib97","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib98","article-title":"Oncolytic viruses: a novel therapeutic approach for pancreatic cancer","volume":"33","author":"Esteves","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","article-title":"Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer","volume":"20","author":"Barton","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.01.009_bib100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"issue":"7781","key":"10.1016\/j.cytogfr.2026.01.009_bib101","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.01.009_bib102","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.01.009_bib103","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000488917","article-title":"Immunotherapy and combination strategies in pancreatic cancer: current status and emerging trends","volume":"41","author":"Cheung","year":"2018","journal-title":"Oncol. Res Treat."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib104","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib105","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.01.009_bib106","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1089\/jir.2022.0043","article-title":"A protease activatable interleukin-2 fusion protein engenders antitumor immune responses by interferon gamma-dependent and interferon gamma-independent mechanisms","volume":"42","author":"Norville","year":"2022","journal-title":"J. Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib107","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113588","article-title":"Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma","volume":"381","author":"Shen","year":"2025","journal-title":"J. Control Release"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.01.009_bib109","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1021\/acs.bioconjchem.4c00379","article-title":"Suppressing pancreatic cancer survival and immune escape via nanoparticle-modulated STING\/STAT3 axis regulation","volume":"35","author":"Li","year":"2024","journal-title":"Bioconjug Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12951-024-03010-5","article-title":"Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis","volume":"22","author":"Palencia-Campos","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.cytogfr.2026.01.009_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123147","article-title":"High-density lipoprotein-based nanoplatform reprograms tumor microenvironment and enhances chemotherapy against pancreatic ductal adenocarcinoma","volume":"318","author":"Huang","year":"2025","journal-title":"Biomaterials"},{"issue":"18","key":"10.1016\/j.cytogfr.2026.01.009_bib112","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1039\/D0BM00916D","article-title":"Co-inhibition of the TGF-\u03b2 pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"Biomater. Sci."},{"issue":"38","key":"10.1016\/j.cytogfr.2026.01.009_bib113","article-title":"Cascade-targeted nanoparticles for enhanced gemcitabine delivery and adenosine metabolism modulation to overcome treatment resistance in pancreatic cancer","volume":"12","author":"Fan","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202303033","article-title":"A chemoimmunotherapy nanogel enables efficient delivery of interleukin-2 and induction of immunogenic cell death for effective cancer therapy","volume":"34","author":"Mu","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.01.009_bib115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418306122","article-title":"Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and \u03b2-elemene combination therapy","volume":"122","author":"Zhu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2-3","key":"10.1016\/j.cytogfr.2026.01.009_bib116","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0162-3109(97)00041-6","article-title":"Vascular leak syndrome: a side effect of immunotherapy","volume":"37","author":"Baluna","year":"1997","journal-title":"Immunopharmacology"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib118","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2326-6066.CIR-17-0495","article-title":"Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs","volume":"6","author":"Dougan","year":"2018","journal-title":"Cancer Immunol. Res"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.01.009_bib119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13046-024-03238-x","article-title":"Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice","volume":"44","author":"Carbone","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.01.009_bib120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010685","article-title":"IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors","volume":"13","author":"Nash","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.01.009_bib121","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/2767-9764.CRC-24-0185","article-title":"Phase I study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors","volume":"4","author":"Koyama","year":"2024","journal-title":"Cancer Res Commun."},{"issue":"16_","key":"10.1016\/j.cytogfr.2026.01.009_bib122","article-title":"Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)","volume":"40","author":"Chamie","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2026.01.009_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1472714","article-title":"Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients","volume":"15","author":"Seery","year":"2025","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.01.009_bib124","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","article-title":"Simultaneous targeting of PD-1 and IL-2R\u03b2\u03b3 with radiation therapy inhibits pancreatic cancer growth and metastasis","volume":"41","author":"Piper","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:21:06Z","timestamp":1778520066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610126000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":124,"alternative-id":["S1359610126000171"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.01.009","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}